Golimumab

From Wikipedia, the free encyclopedia
  (Redirected from Simponi)
Jump to: navigation, search
Golimumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target TNFα
Clinical data
Trade names Simponi
AHFS/Drugs.com monograph
MedlinePlus a610010
Licence data EMA:Link, US FDA:link
Pregnancy cat.  ?
Legal status ℞-only (US)
Routes Subcutaneous injection
Identifiers
CAS number 476181-74-5 N
ATC code L04AB06
UNII 91X1KLU43E YesY
KEGG D04358 YesY
ChEMBL CHEMBL1201833 N
Chemical data
Formula C6530H10068N1752O2026S44 
Mol. mass 147 kDa
 N(what is this?)  (verify)

Golimumab (CNTO 148)[1] is a human monoclonal antibody which is used as an immunosuppressive drug and marketed under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule[2] and hence is a TNF inhibitor.

Golimumab was developed by Centocor and is approved in Canada[3] and the United States[4] as a once monthly subcutaneous treatment for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.[5]

Johnson & Johnson, the parent company of Centocor, requested approval from European Medicines Agency (EMEA) for the use of golimumab as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.[6] Golimumab is marketed by Merck & Co, Inc. in Europe, pending final arbitration between J&J and Merck.[7][8]Simponi received marketing authorisation from the European Medicines Agency on 1 October 2009.[9]

[edit] Efficacy

Large, randomized, double-blind trials in patients with rheumatoid arthritis have shown that golimumab in combination with methotrexate was more effective than methotrexate alone.[10]

[edit] References

  1. ^ Mazumdar, Sohini; David Greenwald (2009). "Golimumab". mAbs 1 (5): 422–431. doi:10.4161/mabs.1.5.9286. http://www.landesbioscience.com/journals/mabs/article/9286/. 
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Golimumab, American Medical Association.
  3. ^ "Health Canada Approves Simponi (Golimumab) For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis". http://www.centocororthobiotech.com/cobi/viewDocumentByTitleAlias.html?title=PR_SIMPONI_CANADIAN_APPROVAL.  Apr 2009
  4. ^ FDA Approves Simponi
  5. ^ "FDA clears potential blockbuster arthritis drug". North County Times. Associated Press (Lee Enterprises). 24 April 2009. http://www.nctimes.com/business/article_95a13fa4-8492-5080-8ee0-bbce644fb21b.html. Retrieved 23 October 2010. 
  6. ^ Johnson & Johnson Reports 2008 First-Quarter Results
  7. ^ FDA approves Johnson & Johnson rheumatoid arthritis drug golimumab
  8. ^ [1] Merck sees fast ruling in J&J Remicade arbitration
  9. ^ "Simponi European Public Assessment Report". European Medicines Agency. http://www.emea.europa.eu/humandocs/Humans/EPAR/simponi/simponi.htm. Retrieved 2009-11-15. 
  10. ^ Oldfield V, Plosker GL.[2].Biodrugs 2009;23(2):125-135.doi: 10.2165/00063030-200923020-00005.
Intracellular
(initiation)
Macrolides/
other IL-2 inhibitors
TNF-α inhibitor
Intracellular
(reception)
Extracellular
Serum target
(noncellular)
Cellular target
Unsorted
-cept (Fusion)
Immune system ("-l(i[m])-")
Human ("-limu-")
Mouse ("-limo-")
Chimeric ("-lixi-")
Humanized ("-lizu-")
Chimeric + humanized
("-lixizu-")
Interleukin ("-k(i[n])-")
Human ("-kinu-")
Humanized ("-kizu-", "-kinzu-")
Inflammatory lesions ("-les-")
Mouse ("-leso-")


Stub icon This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.
Stub icon This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Retrieved from "http://en.wikipedia.org/w/index.php?title=Golimumab&oldid=469151661"
Personal tools
Namespaces
Variants
Actions
Navigation
Interaction
Toolbox
Print/export
Languages